Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Diana Dawson
Regulatory Coordinator II
Cancer Center Division
Full Page
Overview
Research
More
Collaboration
(13)
Rachna Shroff
Mutual work: 16 Proposals﹒11 Grants
Collaboration Details
Hina Arif Tiwari
Mutual work: 7 Proposals﹒6 Grants
Collaboration Details
Michele Chu-Pilli
Mutual work: 1 Grant
Collaboration Details
Bital Savir-Baruch
Mutual work: 1 Proposal
Collaboration Details
Brianna Denton
Mutual work: 7 Proposals﹒1 Supervisor﹒5 Grants
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(13)
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre
Active
·
2024
·
$0 / $548.6K
·
External
oncology,
clinical trials,
chemotherapy,
cancer treatment,
targeted therapy
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator's Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/
Active
·
2024
·
$0 / $434.6K
·
External
clinical trials,
cancer treatment,
monotherapy
A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SOC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors
Active
·
2023
·
$0 / $825.5K
·
External
oncology,
clinical trials,
immunotherapy,
cancer treatment,
drug efficacy
A Phase 1 Dose-Escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors and Lymphomas
Active
·
2023
·
$0 / $684.8K
·
External
cancer treatment,
drug trial,
dose escalation,
solid tumors,
lymphomas
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Active
·
2023
·
$0 / $568.2K
·
External
colorectal cancer,
treatment,
clinical trial,
dkn-01,
chemotherapy
Page 1 of 3
Previous page
Next page
